### Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

HALOZYM Form 4 June 01, 200	IE THERAPEU <sup>,</sup> )7	TICS INC								
FORM									OMB AF	PROVAL
	UNITE	O STATES			AND EX( , D.C. 205		NGE C	OMMISSION	OMB Number:	3235-0287
Check th if no lon				0	·				Expires:	January 31,
subject t Section Form 4 c	F CHAN	IGES IN SECUF			L OWN	ERSHIP OF	Estimated a burden hour response			
Form 5 obligation may con <i>See</i> Instr 1(b).	tinue. Section 1	7(a) of the	Public U	tility Hol		ipany	Act of	Act of 1934, 1935 or Section )	1	
(Print or Type	Responses)									
1. Name and A Lim Jonath	Address of Reportin an E	ng Person <u>*</u>	Symbol HALOZ	ZYME TI	HERAPE		6	5. Relationship of Issuer	Reporting Pers	
			INC [H	ALO]				(Check	i un applicable	,
(Last) C/O HALO	(First)	(Middle)	3. Date of (Month/E 05/31/2	-	ransaction			X Director X Officer (give below)	title Othe below)	Owner er (specify
THERAPE	UTICS, INC., 1 O VALLEY RE		0010112					Pre	sident, CEO	
	(Street)			endment, Dannent, Dannent, Dannen, D	ate Original <sup>r)</sup>			6. Individual or Jo Applicable Line) _X_ Form filed by C		
SAN DIEG	O, CA 92121							Form filed by M Person		
(City)	(State)	(Zip)	Tabl	le I - Non-I	Derivative S	Securi	ties Acqu	iired, Disposed of	, or Beneficial	ly Owned
1.Title of Security2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)			n Date, if	3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or			of (D)	5. Amount of Securities6. OwnershipBeneficiallyForm: DirectOwned(D) orFollowingIndirect (I)Reported(Instr. 4)Transaction(s)(Instr. 3 and 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common				Code V	Amount	(D)	Price	(IIIsu: 5 and 4)		
Stock	05/31/2007			M <u>(1)</u>	12,500	А	\$ 0.39	601,997	D	
Common Stock	05/31/2007			S <u>(1)</u>	200	D	\$ 10.17	601,797	D	
Common Stock	05/31/2007			S <u>(1)</u>	600	D	\$ 10.21	601,197	D	
Common Stock	05/31/2007			S <u>(1)</u>	100	D	\$ 10.22	601,097	D	

### Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Common Stock	05/31/2007	S <u>(1)</u>	100	D	\$ 10.24	600,997	D
Common Stock	05/31/2007	S <u>(1)</u>	100	D	\$ 10.25	600,897	D
Common Stock	05/31/2007	S <u>(1)</u>	1,000	D	\$ 10.26	599,897	D
Common Stock	05/31/2007	S <u>(1)</u>	1,500	D	\$ 10.27	598,397	D
Common Stock	05/31/2007	S <u>(1)</u>	1,117	D	\$ 10.28	597,280	D
Common Stock	05/31/2007	S <u>(1)</u>	1,400	D	\$ 10.29	595,880	D
Common Stock	05/31/2007	S <u>(1)</u>	1,383	D	\$ 10.3	594,497	D
Common Stock	05/31/2007	S <u>(1)</u>	100	D	\$ 10.31	594,397	D
Common Stock	05/31/2007	S <u>(1)</u>	1,400	D	\$ 10.32	592,997	D
Common Stock	05/31/2007	S <u>(1)</u>	700	D	\$ 10.33	592,297	D
Common Stock	05/31/2007	S <u>(1)</u>	200	D	\$ 10.34	592,097	D
Common Stock	05/31/2007	S <u>(1)</u>	400	D	\$ 10.35	591,697	D
Common Stock	05/31/2007	S <u>(1)</u>	600	D	\$ 10.37	591,097	D
Common Stock	05/31/2007	S <u>(1)</u>	500	D	\$ 10.38	590,597	D
Common Stock	05/31/2007	S <u>(1)</u>	1,500	D	\$ 10.39	589,097	D
Common Stock	05/31/2007	S <u>(1)</u>	1,100	D	\$ 10.4	587,997	D
Common Stock	05/31/2007	S <u>(1)</u>	2,100	D	\$ 10.41	585,897	D
Common Stock	05/31/2007	S <u>(1)</u>	400	D	\$ 10.42	585,497	D
Common Stock	05/31/2007	S <u>(1)</u>	200	D	\$ 10.43	585,297	D
Common Stock	05/31/2007	S <u>(1)</u>	1,100	D	\$ 10.44	584,197	D
	05/31/2007	S <u>(1)</u>	400	D		583,797	D

#### Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Common Stock					\$ 10.45	
Common Stock	05/31/2007	S <u>(1)</u>	100	D	\$ 10.46 583,697	D
Common Stock	05/31/2007	S <u>(1)</u>	100	D	\$ 10.47 583,597	D
Common Stock	05/31/2007	S <u>(1)</u>	200	D	\$ 10.48 583,397	D
Common Stock	05/31/2007	S <u>(1)</u>	100	D	\$ 10.49 583,297	D
Common Stock	05/31/2007	S <u>(1)</u>	400	D	\$ 10.5 582,897	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactionDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ivative Expiration Date urities (Month/Day/Year) quired (A) Disposed of str. 3, 4,		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Common Stock	\$ 0.39	05/31/2007		M <u>(1)</u>		12,500	11/11/2003	11/11/2013	Common Stock	12,500

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
r of the test of the	Director	10% Owner	Officer	Other			
Lim Jonathan E	Х		President, CEO				
C/O HALOZYME THERAPEUTICS, INC.							
11588 SORRENTO VALLEY RD., SUITE 17							

SAN DIEGO, CA 92121

## Signatures

/s/ Jonathan E. Lim

06/01/2007

<u>\*\*</u>Signature of Reporting Person Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares purchased and sold, as applicable, under 10b5-1 Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.